A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD

A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD

DSpace/Manakin Repository

A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD

dc.contributor.author	Klint, Thorsten
dc.contributor.author	Adler, Lenard
dc.contributor.author	West, Scott
dc.contributor.author	Wesnes, Keith
dc.contributor.author	Graff, Ole
dc.contributor.author	Mikkelsen, Birgit
dc.contributor.author	Wilens, Timothy Edwin
dc.date.accessioned	2011-04-08T16:30:39Z
dc.date.issued	2008
dc.identifier.citation	Wilens, Timothy E., Thorsten Klint, Lenard Adler, Scott West, Keith Wesnes, Ole Graff, and Birgit Mikkelsen. 2008. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behavioral and Brain Functions : BBF 4: 24.	en_US
dc.identifier.issn	1744-9081	en_US
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:4817628
dc.description.abstract	Background: NS2359 is a potent reuptake blocker of noradrenalin, dopamine, and serotonin. The aim of the study was to investigate the efficacy, safety and cognitive function of NS2359 in adults with a DSM IV diagnosis of ADHD. Methods: The study was a multi-centre, double-blind, randomized placebo-controlled, parallel group design in outpatient adults (18–55 years) testing 0.5 mg NS2359 vs. placebo for 8 weeks. Multiple assessments including computerized neuropsychological evaluation were performed. Results: There was no significant difference between NS2359 (n = 63) versus placebo (n = 63) on the primary outcome measure reduction in investigator rated ADHD-RS total score (7.8 versus 6.4; p less than 0.45). However, in subjects with the inattentive subtype, there were significantly more responders in the NS2359 group compared to placebo (41% versus 7%; p less than 0.01). For all secondary variables (ADHD-RS patient rated; The Conners Adult ADHD Scale; The Brown Adult Scale, and CGI-improvement scale) there were no significant differences between the two groups; however, in the inattentive subgroup, the response to treatment was significantly larger than to placebo. NS2359 improved composite factor scores of attention, episodic- and working memory. No serious adverse events were reported with insomnia, headaches and loss of appetite most commonly reported as side effects. Conclusion: No overall effect of NS2359 was found on overall symptoms of ADHD. There was also a modest signal of improvement in the inattentive adults with ADHD and cognition warranting further exploration using differing doses.	en_US
dc.language.iso	en_US	en_US
dc.publisher	BioMed Central	en_US
dc.relation.isversionof	doi:10.1186/1744-9081-4-24	en_US
dc.relation.hasversion	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442604/pdf/	en_US
dash.license	LAA
dc.title	A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD	en_US
dc.type	Journal Article	en_US
dc.description.version	Version of Record	en_US
dc.relation.journal	Behavioral and Brain Functions : BBF	en_US
dash.depositing.author	Wilens, Timothy Edwin
dc.date.available	2011-04-08T16:30:39Z
dash.affiliation.other	HMS^Psychiatry-Massachusetts General Hospital	en_US